Brigham and Women's Hospital Articles

Oncology Advances Spring 2015

Receive news, treatment options, research and clinical trials from Brigham and Women's Cancer Center

Issue link: http://brighamandwomens.uberflip.com/i/485884

Contents of this Issue

Navigation

Page 4 of 7

Dana-Farber/Brigham and Women's Cancer Center | 5 Philippe Armand, MD, PhD Medical Oncologist, Center for Hematologic Malignancies Dana-Farber/Brigham and Women's Cancer Center R. Coleman Lindsley, MD, PhD Medical Oncologist, Center for Hematologic Malignancies Dana-Farber/Brigham and Women's Cancer Center Any Hematologic Malignancy • Study of Ipilimumab in Patients With Relapsed Hemato- logic Malignancies after Allogeneic Hematopoietic Cell Transplantation (HCT) – This Phase I/IB study, developed and led by National Principal Investigator Matthew S. Davids, MD, MMSc, is studying the side effects and the optimal dose of ipilimumab in treating patients with re- lapsed hematologic malignancies after donor stem cell transplantation. In a presentation at the ASH meeting, Dr. Davids reported that 10 mg/kg has been well-tolerated for most patients and is showing signs of anti-tumor ac- tivity in patients with both lymphoid and myeloid cancers. The trial is sponsored by the Cancer Therapy Evaluation Program of the National Cancer Institute (CTEP/NCI), and is a multicenter study that Dr. Davids is conducting through the Blood Cancer Research Partnership of the Leukemia & Lymphoma Society (BCRP/LLS). For more information regarding this trial, please contact Matthew S. Davids, MD, MMSc, at (617) 632-6331 or mdavids@partners.org. Matthew S. Davids, MD, MMSc Medical Oncologist, Center for Hematologic Malignancies Dana-Farber/Brigham and Women's Cancer Center Kenneth C. Anderson, MD, Director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber/ Brigham and Women's Cancer Center and Chief of the Division of Hemato- logic Neoplasia and Vice Chair of the Joint Program in Transfusion Medicine, has been elected to a one-year term as Vice President of the American Society of Hematology (ASH), followed by successive terms as President-Elect and President. Dana-Farber/Brigham and Women's Cancer Center News Leadership Announcements Daphne A. Haas-Kogan, MD, has been appointed Chair of the Depart- ment of Radiation Oncology at Dana-Farber/Brigham and Women's Cancer Center, effective July 1, 2015. Dr. Haas-Kogan has an active labora- tory-based research program that is investigating novel therapeutic agents for adult and childhood brain tumors, as well as pediatric malignancies. Now Online from Dana-Farber/Brigham and Women's Cancer Center Dana-Farber/Brigham and Women's Cancer Center has launched a new online resource to provide comprehensive information on precision cancer medicine including: • Latest thinking in precision cancer medicine from our re- searchers and clinicians, including specialized information in key diseases • A searchable database of clinical trials that focus on tar- geted therapies by disease, gene and mutation • Genomic research studies and findings, including infor- mation on Profile, our large scale cohort, where over 10,000 tumor profiles have been generated, testing for over 300 DNA mutations • Referral and access information www.precisioncancermedicine.org

Articles in this issue

view archives of Brigham and Women's Hospital Articles - Oncology Advances Spring 2015